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ABSTRACT 
 
There are two vascular systems in the body, for blood and lymph, and both are 
indispensable for embryonic development. The closed circuit of blood vessels is 
responsible for oxygen and nutrient delivery to all compartments of the body 
and removal of CO2 and waste products from tissues. The open-ended 
lymphatic system works as a return route for fluid, immune cells and dietary 
lipids into the blood circulation. The heart is the central engine for blood flow 
whereas lymphatic flow is achieved by skeletal and smooth muscle contraction 
around the lymphatic vessels. Differences between the blood vascular and 
lymphatic systems are apparent, from the molecular to the functional level. 
However, the two types of vessels also share a number of signaling molecules 
and building blocks of vessels. 
 
The purpose of the studies presented in this thesis was to expand our 
knowledge about Vascular Endothelial Growth Factors (VEGFs) and their 
receptors in development and pathological conditions. In the first study, we 
found, surprisingly, that VEGFR-3, the receptor for the principal lymphatic 
vessel growth factor, VEGF-C, is crucial for the normal patterning of the 
developing blood vessels and that endothelial deletion of Vegfr3, but not 
VEGFR-3-blocking antibodies, leads to excessive blood vessel sprouting and 
branching. Furthermore, macrophages that express the VEGFR-3 and VEGFR-
2 ligand VEGF-C localized to the vessel branchpoints, and Vegfc heterozygous 
mice exhibited inefficient angiogenesis characterized by decreased vascular 
branching. Our second study focused on the pathological aspect of the 
atherosclerosis. By using the transgenic mouse that overexpress soluble 
VEGFR-3 (VEGF-C/D trap) we could link the impaired lymphatic vessels to 
lipoprotein metabolism, increased plasma cholesterol levels, and enhanced 
atherogenesis. In the third project we focused on the role of lymphangiogenic 
growth factors in the steady-state homeostasis of lymphatic vessels in adult 
mice. Our findings from this study indicated that the lymphangiogenic growth 
factors provide trophic and dynamic regulation of the intestinal lymphatic 
vasculature, which could be especially important in the dietary regulation of 
adiposity and cholesterol metabolism. Finally in the last study we discovered a 
new role of VEGF-C in the embryonic development. To our surprise, we found a 
striking VEGF-C dependent phenotype with defective fetal liver erythropoiesis 
that resulted severe anemia in the Vegfc deteled embryos. 
 
These studies have revealed a new viewpoint regarding the VEGF-C/VEGFR-3 
pathway in embryonic and pathological conditions. With these results, our 
understanding of the VEGF family members has expanded beyond the blood 
and lymphatic vessel. Hopefully, this new knowledge will improve the 
possibilities to target the VEGF-C/VEGFR-3 pathway for the treatment of 
human diseases such as atherosclerosis, obesity, and vascular diseases. 
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REVIEW OF THE LITERATURE 
 
Introduction 
 
Vascular endothelial growth factors (VEGFs) and their receptors are the main 
regulators of endothelial cell growth, proliferation and migration leading to 
vessel growth. In general terms, the VEGF/VEGFR-2 pathway is crucial for 
blood vessel growth (angiogenesis) during embryonic development, whereas 
lymphatic vessel growth is dependent of VEGF-C/VEGFR-3 signaling. Studies 
using transgenic mouse models during the past three decades have revealed 
that these signaling molecules are required for normal vascular development. 
As an example, deletion of VEGF-C causes embryonic lethality around 
embryonic day (E) 16.5 and detailed inspection of these embryos revealed that 
they lack lymphatic vessels (Karkkainen et al., 2004). However, constitutive 
deletion of Vegfr3, the main VEGF-C receptor for lymphangiogenesis, arrested 
cardiovascular development at E9.5, leading to embryonic lethality even before 
the beginning of differentiation of the first lymphatic endothelial cells (Dumont et 
al., 1998). Thus VEGFR-3 has a dual role in blood and lymphatic vasculatures. 
 
While the vascular developmental aspects of these key players have been 
confirmed in groundbreaking studies using knockout mice, the roles of these 
same molecules have been studied in several pathological conditions. In cancer 
and lymphedema, our knowledge of the molecular interactions required for new 
vessel growth has increased rapidly. The aim of the studies presented in this 
thesis has been to investigate more thoroughly the other roles that the VEGF-
C/VEGFR-3 pathway has during development and in pathological conditions. 
Studies presented here indicate embryonic function of VEGF-C/VEGFR-3 
beyond the lymphatic vessel regulation. In adult mice, our purpose was to 
clarify how these molecules regulate homeostasis under quiescent and 
challenged or pathological conditions. Mainly, all of the studies have been done 
using transgenic mouse models, which provide a way of validating the 
physiological and pathological interactions related to human diseases.  
Development of vascular networks 
 
The role of the blood circulatory system is to carry oxygen, nutrients, different 
types of blood cells and signaling molecules, such as hormones, to the cells 
and remove carbon dioxide and waste products from the peripheral tissues. 
This constant flow is based on the pumping mechanism of the heart, which 
together with other mechanisms like smooth muscle cell contractions in the 
arteries keeps blood flow and pressure at a certain level. Main components of 
the blood are erythrocytes, which are responsible for gas exchange and various 
types of leukocytes, including the immune cells of the body. The acellular part 
of the blood is called plasma, which can be described as a protein-rich fluid. 
The blood vessel network can be divided by the size of the vessels to large 
arteries, arterioles, capillaries, venules and veins. Altogether the length of the 
blood vessel system is 100 000 kilometers and the area covered by the vessel 
endothelium is about half of an ice hockey rink All tissues in the body, except 
the cornea and the cartilage are vascularized (Cines et al., 1998). 
 
? ?
Lymphatic vasculature differs from blood vasculature in a few important aspects 
(Figure 1). First, lymphatic vasculature participates in the maintenance of the 
fluid balance in the body, in immune cell trafficking and in dietary lipid 
absorption from the gut. Second the lymphatic vessel network is not closed like 
the blood circulatory system. Lymphatic capillaries are blind-ended; they can be 
found in most of the tissues. Third, flow in lymphatic vessels is not driven by a 
particular organ, unlike in the blood circulatory system. Instead, it is controlled 
by the pulsatile activity of the lymphatic collector vessels, which contain valves 
to prevent lymph backflow and which are responsible for returning the lymph 
back to blood circulation (Bazigou and Makinen, 2013). At the cellular level 
blood endothelial cells (BECs) differ from lymphatic endothelial cells (LECs) by 
their molecular signature and by their interactions with the environment (Lohela 
et al., 2009).  
 
?
Figure 1. Differences between blood and lymphatic vessels. A) Simplified schematic of 
fundamental differences between blood and lymphatic vessels. Blood vessels are a closed 
system with constant pumping from the heart, and lymphatic vessels are blind-ended, 
unidirectional vessels with valve structures in the collector vessels. B) Blind-end lymphatic 
vessels in the gut known as lacteals are responsible for dietary lipid absorption from the 
intestinal lumen. Blood vessels are presented here in red and blue, and lymphatic vessels in 
green. An important cell type responsible for barrier function in the intestine, the enterocytes, is 
shown in brown and smooth muscle cells in orange. C) Immunofluorescence images from the 
intestinal wall of mice. Scale bar 400 μm. 
?
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Blood vascular system 
 
In mouse embryos, the first functional organ system is the cardiovascular 
system. In mice, this system can be distinguished already at E7.0 by expression 
of VEGFR-2 in angioblasts, which are mesodermal cells that differentiate to 
primitive endothelial cells (Dumont et al., 1995). These cells are responsible for 
formation of blood islands in the yolk sac, where the precursor cells of the 
endothelia and the hematopoietic cells interact (Medvinsky et al., 2011). These 
cells then form the primitive vascular plexus of the embryo in a process called 
vasculogenesis (Risau and Flamme, 1995). Later, the primary means for new 
vascular formation is angiogenesis, which can be described as formation of new 
vessels from existing ones via sprouting or splitting (Djonov et al., 2000). 
Several different vascular growth factors plus other signaling molecules, 
hypoxia and blood flow are responsible for the angiogenic steps that are 
necessary for proper vascular formation during development (Udan et al., 
2013). This process includes the migration and proliferation of endothelial cells 
and branching and remodeling of the vasculature. The main molecular driver 
behind angiogenesis is the VEGF/VEGFR-2 pathway. Blood vessel growth and 
its directionality are mediated by a VEGF gradient, which reflects the hypoxia 
gradient or cellular source (e.g. macrophage) of VEGF (Ruhrberg et al., 2002). 
The endothelial cells will subsequently differentiate to obtain arterial or venous 
identity, which is regulated by expression changes of, for instance  Eph 
receptors and Notch ligands (Chong et al., 2011). Still later, some specific 
venous ECs will differentiate to LECs starting from the cardinal vein (Yang and 
Oliver, 2014). 
 
During the postnatal period angiogenesis continues in the growing tissues 
mainly via sprouting from previously established vascular beds. During the 
sprouting angiogenesis, ECs are highly responsive to external signals. The ECs 
have the ability to upregulate and downregulate signaling cascades during the 
vascular expansion (Jakobsson et al., 2009). The VEGFR-Notch pathway is 
well known in this process. The “Tip” cells are responsible for interaction with 
VEGFs via VEGFRs and the interaction induces Notch ligand, like Dll4, 
expression in these cells; the Notch signaling in the “stalk” cells form a 
stabilizing mechanism for gradient-dependent sprouting (Hellstrom et al., 2007; 
Tammela et al., 2008). Tip and stalk cells show differences in gene expression, 
with tip cells expressing somewhat more VEGFR-2 (Gerhardt et al., 2003) and 
stalk cells more decoy-receptor VEGFR-1 (Krueger et al., 2011). 
Lymphatic vasculature 
 
Lymphatic vasculature was long considered a passive “drainage” of fluid and 
other components that had escaped from blood circulation. In the recent 
decades, this view has changed dramatically. The master regulator of the 
differentiation of lymphatic vessels from blood vessels is the Prospero 
Homeobox 1 (Prox1) gene (Wigle and Oliver, 1999). Although Prox1 can be 
found in some blood vessels, e.g. in venous valves (Bazigou et al., 2011) and 
cardiac valves (Rodriguez-Niedenfuhr et al., 2001), it has been shown to be a 
key transcription factor for the early steps of LEC differentiation from the 
embryonic veins. This has been shown also in the experimental setups where 
overexpression of Prox1 in BECs alters their expression pattern toward LECs 
(Hong et al., 2002; Petrova et al., 2002).  
? ??
 
During development several other molecules have been indicated to play a role 
in the early steps of lymphangiogenesis. The COUP-TFII and SOX18 
transcription factors are responsible for Prox1 activation at E9.5 (Koltowska et 
al., 2013). On the other hand, Prox1 expression is responsible for VEGFR-3 
upregulation in the common cardinal vein (Wigle et al., 2002). At E9.5 VEGFR-3 
is highly expressed in the developing blood vasculature, and its complete 
absence leads to embryonic death one day later, at E10.5, because of 
cardiovascular defects (Dumont et al., 1998). From the cardinal vein, LECs start 
their budding to form the primitive lymph sac around E10-E10.5. This step is 
dependent on VEGF-C and its absence leads to failure of lymph sac formation 
(Hagerling et al., 2013; Karkkainen et al., 2004). Recent findings have 
highlighted the importance of VEGF-C processing throughout this process. The 
proteolytic activation of VEGF-C requires cooperation of the secreted factor 
collagen and calcium binding EGF domains 1 (CCBE1) plus a disintegrin and 
metalloproteinase with thrombospondin motifs 3 (ADAMTS3) (Bos et al., 2011; 
Bui et al., 2016; Janssen et al., 2016; Jeltsch et al., 2014; Le Guen et al., 2014). 
 
Growth of the lymphatic vessels starts mostly from embryonic veins; it is 
directed towards the VEGF-C growth factor gradient in embryonic 
lymphangiogenesis (Yang and Oliver, 2014). However, recent fascinating 
findings have provided strong evidence that in several tissues there are other 
cellular sources that constitute non-venous origins of lymphatic vessels. 
Lymphatic vessel formation in the heart (Klotz et al., 2015), mesentery 
(Stanczuk et al., 2015) and skin (Martinez-Corral et al., 2015) is based on a 
process called lymphvasculogenesis, where assembly of cells of hemogenic 
origin forms lymphatic vessel structures. When the primary lymphatic plexus 
has been established, it will go through maturation, which includes hierarchical 
transformation that leads to blind-end primary capillaries to pre-collectors and 
collecting vessels (Yang and Oliver, 2014). An important step in this phase is 
the formation of lympho-venous valves, which prevent blood backflow to the 
lymphatic system (Hess et al., 2014). Collecting lymphatic vessels recruit 
smooth muscle cells (SMCs) and form a surrounding basement membrane 
simultaneously as the lymphatic valves are formed to the collectors via a Foxc2 
transcription factor-dependent pathway (Norrmen et al., 2009). Upon 
maturation, the expression patterns of mature lymphatic vessel markers change 
from the developmental stage where LYVE-1, Prox-1, and VEGFR-3 are all 
fairly uniformly expressed in the primitive lymphatic plexuses. After maturation, 
the valve regions have higher expression of VEGFR-3 and Prox1 than the 
intervening lymphangions, the functional unit of a lymphatic vessel that locates 
between two valves, in the collector vessels, whereas LYVE-1 expression is 
decreased in the collectors and only maintained in the capillaries (Norrmen et 
al., 2009). Lymphatic capillaries change their junctions from zipper-like to 
button-like after birth (Baluk et al., 2007; Zheng et al., 2014). Angiopoietin 
(Ang2) signaling regulates this change and it also contributes to vessel network 
formation during embryonic development (Zheng et al., 2014).  
 
The lymphatic vessel network spreads throughout the skin and into most of the 
internal organs. New studies have indicated that the lymphatic vessels extend 
also to the eye and to the central nervous system (Aspelund et al., 2014; 
Louveau et al., 2015). There are three main functions for which lymphatic 
vessels are responsible: dendritic cell trafficking from tissues to lymph nodes 
?? ??
(Miteva et al., 2010; Randolph et al., 2005), regulation of tissue fluid balance 
(Dongaonkar et al., 2009), and absorption of dietary lipids (Iqbal and Hussain, 
2009). The immune cell trafficking is closely related to the events of 
inflammation and will be discussed later in more detail. Regulation of tissue fluid 
homeostasis is an important function that has been from reviewed from a 
physiological perspective (Wiig and Swartz, 2012). The absorption of dietary 
lipids and lipid-soluble vitamins is the third well-described function of lymphatic 
vessels in normal conditions (Iqbal and Hussain, 2009). The main role of the 
lymphatic vessels in the intestine is to take up and transport chylomicrons, 
which have been packed and processed by the enterocytes, to the blood 
circulation via the thoracic duct (Dixon, 2010). A few studies have now shown 
that lymphatic vessels can maintain sodium balance via the VEGF-C/VEGFR-3 
pathway (Machnik et al., 2009; Wiig et al., 2013; Zhang et al., 2015). These 
findings however have not, however, yet convinced all researchers in the field. 
Vascular endothelial growth factor family 
 
Five main VEGFs and their three receptors with specific ligand binding and 
signaling patterns have been described to control blood and lymphatic 
endothelial cell proliferation and migration (Figure 2). Their molecular 
interactions are discussed below.  
 
 
 
 
Ligands 
VEGF, VEGF-B and PlGF 
 
VEGF was discovered and named vascular permeability factor (VPF) in 1983 
(Senger et al., 1983) and it was cloned six years later (Ferrara and Henzel, 
1989). It is the best-characterized angiogenic factor. Deletion of a single allele 
of Vegf leads to embryonic lethality around E11.5 because of defects in blood 
vessel development (Carmeliet et al., 1996; Ferrara et al., 1996). VEGF binds to 
VEGFR-1 and VEGFR-2 (de Vries et al., 1992; Quinn et al., 1993) and to the 
neuropilin receptors 1 and 2 (Gluzman-Poltorak et al., 2000; Soker et al., 1998). 
Its expression can be detected already at E7.0 in the developing embryo 
(Dumont et al., 1995), highlighting the importance of this growth factor in early 
Figure 2. VEGF family. Main 
components of the VEGF family 
without soluble forms of the 
receptors or occasionally 
occurring heterodimers. The 
VEGF-C/VEGFR-3 axis is 
highlighted among other 
described interactions.  
? ??
development. Vegf gene expression dosage is critical; even a moderate 
increase of its expression leads to embryonic death at E12.5 because of 
defective heart development. VEGF acts as a paracrine factor, but autocrine 
signaling has been reported in endothelial cells (Lee et al., 2007). One of the 
principal regulators controlling the expression of Vegf is hypoxia via the 
hypoxia-inducible factor (HIF)-1, but many inflammatory cytokines, hormones, 
and growth factors can also induce Vegf gene activation (Chung and Ferrara, 
2011). The main role of the VEGF is to boost EC growth and survival (Alon et 
al., 1995; Benjamin et al., 1999; Benjamin and Keshet, 1997). This occurs 
mainly via the MAPK pathway, the PI3K-Akt pathway, and downstream proteins 
mediating anti-apoptotic signals (Gerber et al., 1998a; Gerber et al., 1998b). 
Studies have shown that VEGF is a potent inducer of vascular permeability 
(Dvorak et al., 1995) and inflammation (Larcher et al., 1998).  Overexpression 
of VEGF via , for example, a viral vector induces robust and uncontrolled 
angiogenesis in several models (Detmar et al., 1998; Kenyon et al., 1996; 
Leung et al., 1989; Pettersson et al., 2000). Because of the vascular leakage 
and uncontrolled robust angiogenesis, the clinical use of the VEGF is very 
limited. Besides its roles in angiogenesis, VEGF functions in other processes in 
various tissues. It can boost bone formation (Midy and Plouet, 1994), affect lung 
maturation (Compernolle et al., 2002), and enhance neuronal proliferation 
(Zachary, 2005). VEGF can induce lymphatic vessel hyperplasia via VEGFR2, 
which is expressed at low levels in the lymphatic vessels (Nagy et al., 2002; 
Wirzenius et al., 2007). 
 
VEGF-B, originally named as VRF (VEGF-related factor) was discovered in 
1996 (Grimmond et al., 1996; Olofsson et al., 1996). VEGF-B deficiency does 
not affect normal mouse development (Aase et al., 2001). VEGF-B is robustly 
expressed in the heart, skeletal muscle, and some other tissues such as brown 
fat in embryos and adults (Aase et al., 1999; Nash et al., 2006). VEGF-B does 
not function as a traditional angiogenic factor comparable to VEGF. This has 
been shown in studies where it is overexpressed in several tissues without 
causing angiogenesis or vascular growth (Bhardwaj et al., 2003; Lahteenvuo et 
al., 2009; Li et al., 2008). However, VEGF-B does induce growth of coronary 
vasculature that protects the heart from myocardial infarction (Bry et al., 2010; 
Huusko et al., 2012; Karpanen et al., 2008; Kivela et al., 2014). VEGF-B has 
been linked to vascular remodeling in adipose tissue, adipose tissue 
metabolism, and insulin sensitivity via its function as a competitive ligand for the 
VEGF/VEGFR-1 pathway (Hagberg et al., 2010; Hagberg et al., 2012; Robciuc 
et al., 2016).  
 
PlGF is one of the oldest members of the VEGF-family discovered over 
aquarter of a century ago (Maglione et al., 1991). Similarly to VEGF-B, it binds 
to VEGFR-1 and NRP-1 (Migdal et al., 1998; Park et al., 1994). PlGF-deficient 
mice are viable, but unlike the VEGF-B deficient mice, they have defects in 
angiogenesis and arteriogenesis in conditions, such as wound healing and 
inflammation, which have not been reported in the VEGF-B mice (Carmeliet et 
al., 2001; Freitas-Andrade et al., 2012). PlGF also differs from VEGF-B in its 
potential to induce angiogenesis (Luttun et al., 2002), inflammation (Oura et al., 
2003), and vascular permeability (Odorisio et al., 2002) Because of these 
findings, it seems that in the pathological situations the inhibition of PlGF may 
be beneficial (De Falco, 2012).  
?
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VEGF-C and VEGF-D 
 
VEGF-C and VEGF-D was isolated and cloned roughly twenty years ago as a 
ligands that can bind to VEGFR-3 and VEGFR-2 (Achen et al., 1998; Joukov et 
al., 1996). VEGF-C and VEGF-D growth factors differ from other VEGF family 
members by their proteolytic processing. They are expressed as precursor 
proteins, which can only bind to VEGFR-3 (Joukov et al., 1996; Lee et al., 
1996). In humans both proteins are cleaved by furin or the proprotein 
convertases PC5 and PC7, which increase their binding activity towards 
VEGFR-3 (McColl et al., 2003; McColl et al., 2007; Siegfried et al., 2003). In 
humans, both proteins can be further processed by N-terminal cleavage to 
produce the fully processed forms (VEGF-C/D-ΔNΔC), which can bind to and 
activate VEGFR-2 and VEGFR-3 (Achen et al., 1998; Joukov et al., 1996; 
Joukov et al., 1997). The mouse VEGF-C-ΔNΔC can also bind to VEGFR-2 
(Joukov et al., 1996), whereas VEGF-D-ΔNΔC cannot (Baldwin et al., 2001).  
 
Two different VEGF-C mRNA splice variants have been reported in mice and 
three in humans, but the shorter forms are poorly understood (Lee et al., 1996). 
VEGF-C is the main lymphangiogenic growth factor during development. During 
the development of the mouse, lack of Vegfc leads to complete lymphatic 
vessel growth arrest and failure of the primary LECs to bud out from the 
cardinal vein, resulting embryonic death around E16.5 (Karkkainen et al., 2004). 
Vegfc heterozygous mice die during the first weeks after birth because of lipid 
absorption problems; a few mice may survive in certain genetic backgrounds to 
weaning age (P21). However, also these mice develop peripheral edema 
because of hypoplastic cutaneous lymphatic vessels (Karkkainen et al., 2004). 
The expression of VEGF-C starts at about E8 near the areas where the primary 
budding of LECs begins from veins (Karkkainen et al., 2004; Kukk et al., 1996). 
VEGF-C has also a role in coronary artery development in the heart (Chen et 
al., 2014a; Chen et al., 2014b). In the developing brain, VEGF-C expression 
triggers VEGFR-3+ neural progenitor proliferation in the olfactory bulb and in 
glial precursor cells in the optic nerve (Le Bras et al., 2006). Studies in zebrafish 
have indicated that VEGF-C is crucial for the growth of axons of motor neurons 
via VEGFR-3 signaling (Kwon et al., 2013). In humans, VEGF-C  expression 
has been analyzed both during the fetal period and in adult tissues (Partanen et 
al., 2000). Especially strong expression was observed in endocrine organs such 
as the thyroid, the adrenal medulla, and the pancreas (Partanen et al., 2000).  
 
VEGF-C signaling via VEGFR-3 is crucial for LEC growth and survival via PI3 
kinase-dependent Akt activation and PKC-dependent p42/p44 MAPK signaling 
(Makinen et al., 2001b). Adenoviral overexpression of VEGF-C in the airways 
induces sprouting lymphangiogenesis (Baluk et al., 2005), and the same 
outcome can be seen when it is overexpressed in the skin of transgenic mice 
(Jeltsch et al., 1997). Lymphatic vessel growth in the tumors is mostly VEGF-C- 
dependent and VEGF-C has been implicated in tumor metastasis to the sentinel 
lymph nodes and other organs (Hirakawa et al., 2007; Skobe et al., 2001a; 
Valtola et al., 1999).  
 
VEGF-D was originally named as c-fos-induced growth factor (FIGF) for 
fibroblastic cells, and after its binding affinity to VEGFR-2 and VEGFR-3 was 
discovered it was re-named as VEGF-D (Achen et al., 1998; Orlandini et al., 
1996). VEGF-D is dispensable during normal lymphatic vessel growth, even 
? ??
though it is expressed in several tissues during development (Avantaggiato et 
al., 1998; Baldwin et al., 2005). VEGF-D has been reported to affect 
angiogenesis in both zebrafish and mice (Duong et al., 2014; Song et al., 2007).  
Expression of VEGF-D has been detected in several tissues, but its function in 
different tissues is poorly known (Achen et al., 1998). The lymphangiogenic 
effect of VEGF-D has been shown in several pathological situations, such as in 
allergic corneal lymphangiogenesis (Lee et al., 2015), tumor growth (Kopfstein 
et al., 2007; Van den Eynden et al., 2007) and in inflammation (Gordon et al., 
2010). There is speculation that inflammation-associated lymphangiogenesis 
(IAL) is more VEGF-D- than VEGF-C-dependent (Bui et al., 2016). VEGF-D- 
induced lymphangiogenesis has been shown by using transgenic mice 
overexpressing VEGF-D or by viral delivery of this growth factor (Byzova et al., 
2002; Veikkola et al., 2001). VEGF-D can furthermore induce angiogenesis 
when delivered into certain tissues using adenoviral vectors (Anisimov et al., 
2009; Rutanen et al., 2004).  
 
Receptors 
VEGFR-1 and VEGFR-2 
 
VEGFR-1, also known as Fms-like tyrosine kinase 1 (Flt1), was discovered in 
1990 (Shibuya et al., 1990) and two years later it was confirmed to be a 
receptor for VEGF (de Vries et al., 1992). It comprises an extracellular domain 
made up seven immunoglobulin homology domains, a trans-membrane domain 
and a split intracellular tyrosine kinase domain, which is responsible for 
intracellular signaling after ligand binding and receptor dimerization (Tanaka et 
al., 1997). Vegfr1 deficiency leads to embryonic lethality around E9.0 because 
of the unorganized overgrowth of blood vascular endothelium (Fong et al., 
1995). This and other findings suggest that VEGFR-1, which has weak tyrosine 
kinase activity, is not responsible for angiogenesis, rather it acts as a decoy-
receptor for VEGF (Fong et al., 1995; Fong et al., 1999; Hiratsuka et al., 1998). 
During development VEGFR-1 is expressed mainly in hemangioblasts and in 
the adults in the endothelium, monocytes, dendritic cells and hematopoietic 
stem cells (Shibuya, 2001). Recently, VEGFR-1 was found to have an important 
role in adipose tissue metabolism in mice fed a high-fat diet (Robciuc et al., 
2016).   
 
VEGFR-2 is the main receptor for VEGF and it is responsible for developmental 
and pathological angiogenesis (Chung and Ferrara, 2011). It was found as fetal 
liver kinase-1 (Flk1) in mice (Matthews et al., 1991) and kinase-insert domain 
receptor (KDR) in humans (Terman et al., 1991). VEGF/VEGFR-2 signaling 
promotes endothelial cell survival, migration, proliferation, and sprouting (Gille 
et al., 2001). In addition to VEGF binding to VEGFR-2, the processed 
lymphangiogenic factors VEGF-C-ΔNΔC in mice and humans and VEGF-D-
ΔNΔC in humans can activate endothelial cell signaling via VEGFR-2 (Achen et 
al., 1998; Joukov et al., 1997). Vegfr2-deficient embryos die around E9.0 
because of impaired vasculogenesis and hematopoiesis (Shalaby et al., 1995). 
VEGFR-2 is expressed from E7.0 onwards in several compartments of the 
developing embryo (Millauer et al., 1993) and its expression can be detected in 
mature endothelial cells in adults throughout the lifespan (Matsumoto and 
Claesson-Welsh, 2001). Besides endothelial cells, VEGFR-2 is expressed for 
instance, hematopoietic cells (Ziegler et al., 1999) and some neuronal cells 
?? ??
(Yang and Cepko, 1996). Low VEGFR-2 expression can be detected in LECs 
and a selective VEGFR-2 ligand is known to induce lymphatic vessel 
hyperplasia, but not sprouting (Nagy et al., 2002; Wirzenius et al., 2007). 
VEGFR-3 
 
VEGFR-3, also called Fms-like tyrosine kinase 4 (Flt4) was isolated in 1993 
from human leukemia cells (Pajusola et al., 1992). It differs structurally from 
VEGFR-2, as it is proteolytically cleaved in the extracellular domain, but a 
disulfide bond (-S-S-) keeps the fragments together (Pajusola et al., 1994). The 
ligands for VEGFR-3 are VEGF-C and VEGF-D. VEGFR-3 has a dual role in 
embryonic blood and lymphatic vessel development. VEGFR-3 expression 
starts at E8.5 in blood vascular endothelium and Vegfr3 deficiency leads to 
embryonic death because of cardiovascular defects at E9.5 (Dumont et al., 
1998). Later, during embryonic development and postnatal stages, VEGFR-3 
expression is mainly observed in LECs and blocking of this pathway inhibits 
lymphatic vessel growth (Karpanen et al., 2006b; Makinen et al., 2001a; 
Zarkada et al., 2015). Deletion of VEGF-C and VEGF-D causes embryonic 
lethality around E16.5 because of lymphatic vessel defects, indicating that 
VEGFR-3 activity in the early embryonic stages is probably not controlled by 
these two VEGFR-3 ligands (Haiko et al., 2008). VEGFR-3 can form 
heterodimers with VEGFR-2, but detailed in vivo function of this heterodimer is 
incompletely known (Dixelius et al., 2003; Nilsson et al., 2010).  
 
Besides LECs, some BECs express VEGFR-3 in adult tissues. VEGFR-3 can 
be found in fenestrated vessels in several organs, like the liver, spleen, and 
endocrine organs, as well as in high endothelial venules (HEVs) (Lymboussaki 
et al., 1998; Partanen et al., 2000). It has a role in non-endothelial cells such as 
dendritic cells (Hamrah et al., 2004), hematopoietic cells (Thiele et al., 2012) 
and in the corneal epithelia cells (Cursiefen et al., 2006). The variety in VEGFR-
3 expression indicates its pivotal role in several diverse actions maintaining 
body homeostasis.  
Other key molecules in vessel growth during development 
 
Neuropilin (Nrp-1) and Nrp-2 were found to be involved in neuronal guidance 
via acting as receptors for semaphorins (Chen et al., 1997; Kolodkin et al., 
1997). However, a few years later it was established that VEGFs can bind to 
neuropilins, which act as co-receptors for VEGFRs (Fuh et al., 2000; Makinen et 
al., 1999; Migdal et al., 1998; Soker et al., 1998; Whitaker et al., 2001). Nrp1 
deficiency leads to embryonic lethality at E13.5 because of vascular defects 
(Kawasaki et al., 1999). Nrp2 is not necessary for vascular development, 
however Nrp2-deficient mice show abnormalities in lymphatic capillaries (Yuan 
et al., 2002). Combined deletion of both alleles of Nrp1 and Nrp2 leads to 
embryonic death already at E8.5, indicating an early requirement for interplay 
between these two molecules (Takashima et al., 2002). There is complicated 
interplay between VEGFs and Nrps. Some VEGF isoforms bind both Nrps and 
some only one of them (Gluzman-Poltorak et al., 2000; Soker et al., 2002). 
VEGF-B and PlGF can only bind to Nrp1 (Makinen et al., 1999; Migdal et al., 
1998) and VEGF-C and VEGF-D can bind to both neuropilins (Karpanen et al., 
2006a). The current view holds that Nrp1 is responsible for the interactions with 
VEGFR-2 signaling to promote angiogenesis (Soker et al., 2002), while Nrp2 
? ??
interacts with VEGFR-3 to enhance lymphangiogenesis (Karpanen et al., 
2006a).   
 
The TIE receptors (Tyrosine kinase Ig and EGF homology domains) and their 
ligands angiopoietins (Angs) are another crucial growth factor family for 
vascular development (Augustin et al., 2009; Eklund and Saharinen, 2013).  
There are two Tie receptors (Tie1 and Tie2) (Dumont et al., 1992; Partanen et 
al., 1992). Tie receptor expression is restricted for the most part to the 
endothelial cells with a few exceptions, e.g. hematopoietic stem cells (Batard et 
al., 1996). The ligands for Tie2 are called Angiopoietins (Ang1, Ang2, and 
Ang3/4), whereas Tie1 is an orphan receptor, contributing to the Tie-Ang 
signaling via Tie2 (Saharinen et al., 2005). Recent discoveries have shown that 
Tie1 is required for full-scale Tie2 activation in vivo (D'Amico et al., 2014; 
Korhonen et al., 2016). Early characterization with Tie1- and Tie2-deficient mice 
has revealed the obligatory role of TIE receptors in embryonic vascular 
development (Dumont et al., 1994; Patan, 1998; Puri et al., 1995; Sato et al., 
1995). Ang1 deficiency in mice phenocopy the Tie2 KOs (Suri et al., 1996)  Tie-
Ang signaling is based on a cellular microenvironment. Tie receptors are 
located in the cellular junctions of endothelial cells (Fukuhara et al., 2008; 
Saharinen et al., 2008). Mesenchymal cells express Ang1 and this acts in a 
paracrine matter with Tie2 to supports EC survival and this interaction has an 
pivotal role in a stabilization of the endothelial cell junctions and cytoskeleton 
interaction via actin (Gamble et al., 2000; Saharinen et al., 2008). Ang2 is a 
weaker ligand for Tie2 and it can be seen as an antagonist for Tie2, resulting in 
dose-dependent inhibitory effects on the Ang1-Tie2 pathway (Fiedler et al., 
2004). Ang2 expression increases in situations where vascular stability is 
compromised, as in VEGF stimulation, hypoxia, or inflammation-based cytokine 
upregulation (Mandriota and Pepper, 1998). In addition, Ang2 has a mandatory 
role in the LEC junction maturation (Zheng et al., 2014). 
 
Integrins are located on the cell surface and they are responsible for binding of 
matrix proteins like collagen and fibronectin. They form heterodimers and 
contain ?- and ?-subunits (Silva et al., 2008). Integrins interact with well-
known vascular pathways. ? v? 3-integrin is required for full VEGFR-2 
activation via VEGF (Masson-Gadais et al., 2003), and in the Ang/Tie pathway 
destabilization of ECs is ?1-integrin-dependent (Hakanpaa et al., 2015). In the 
lymphatic system, the VEGF-C/VEGFR-3 pathway seems to require ?5?1 
interaction for proper activation (Zhang et al., 2005). ?1-Integrin contact with 
VEGFR-3 can induce receptor phosphorylation followed by cell migration 
independently of the ligand (Wang et al., 2001). 
 
Other growth factors/ligands have been indicated in the past decade to play a 
part in vessel development. Examples include platelet-derived growth factor 
pathway (Armulik et al., 2011), transforming growth factor-? (TGF-?) – bone 
morphogenic protein (BMP) signaling (Cai et al., 2012), and fibroblast growth 
factors (FGFs) (Presta et al., 2005). Apart from these, there are individual 
molecules that have a role in vessel growth and maturation. 
?? ??
 
VEGF-C/VEGFR-3 pathway in pathological conditions  
 
Lymphatic vessels are involved in several human diseases. Below, I describe 
selected pathological conditions in which lymphatic vessels and the VEGF-
C/VEGFR-3 pathway have a crucial function in disease pathogenesis. These 
conditions include cancer and its metastasis, lymphedema, inflammation and 
diseases related to lipid metabolism.  
Cancer 
 
Numerous studies in humans and rodents have shown the importance of 
angiogenesis in tumor growth. For this reason, several anti-angiogenic 
treatments have been developed for inhibition of tumor vascularization (Welti et 
al., 2013). However, the main reason for cancer mortality is metastasis, and a 
key indicator for patient survival is the sentinel lymph node metastases (Tuttle, 
2004), highlighting the importance of lymphatic vessels in cancer biology. 
However, investigations of the lymphatic vessel involvement in tumor growth 
have not yet led to clinical therapeutic applications.  
 
The same growth factors and receptors that regulate developmental 
lymphangiogenesis are also involved in tumor lymphangiogenesis and regulate 
lymphatic vessel invasion by tumor cells. Several human tumor lines express 
high levels of VEGF-C and VEGF-D (He et al., 2004; Hirakawa et al., 2007; 
Sleeman and Thiele, 2009). This indicates that tumor cells actively attract 
lymphatic vessels towards the growing tumor. Studies performed with mice 
have shown that blocking antibodies against VEGFR-3 inhibit tumor metastasis 
to lymph nodes, and in some tumors they also decrease angiogenesis 
(Laakkonen et al., 2007; Rutkowski et al., 2013; Tammela et al., 2008). Several 
upstream factors can promote the VEGF-C/D-VEGFR-3 axis in tumor 
lymphangiogenesis. Prostaglandins have been shown to modulate VEGF-C 
levels in the tumor microenvironment (Su et al., 2004; Timoshenko et al., 2006). 
Hormones such as erythropoietin (Lee et al., 2011) and adrenomedulin 
(Karpinich et al., 2013) increase tumor and sentinel lymph node 
lymphangiogenesis. Although their exact molecular mechanisms are not well 
known, VEGF-C/D-VEGFR-3 is very likely involved. Chemokines have also 
been shown to modulate metastasis to lymphatic vessels. Tumor cells secrete 
VEGF-C and the resulting increase in VEGFR-3 signaling in LECs leads to 
increased CCL21 secretion by the LECs, which can stimulate tumor cell 
migration toward lymphatic vessels (Issa et al., 2009). In the tumor 
microenvironment, lymphangiogenic factors induce sprouting 
lymphangiogenesis, whereas beyond the primary tumor the downstream 
collecting lymphatic vessels expand in response to these factors (He et al., 
2004). This has been related to increased VEGF-C and VEGF-D secretion from 
invasive tumor cells (Hoshida et al., 2006; Karnezis et al., 2012).  
 
Based on the animal models and human studies, blocking of the VEGF-C/D-
VEGFR-3 pathway can inhibit metastasis (Alitalo, 2011; Stacker et al., 2014). 
Several inhibitors and targets are under investigation as candidate drugs that 
could inhibit the VEGF-C/D-VEGFR-3 pathway (Stacker et al., 2014) and 
antibodies that block VEGFR-3 have been tested in phase I clinical trials in 
humans. 
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Lymphedema 
 
Lymphedema is defined by abnormal accumulation of interstitial fluid in tissues, 
usually in the limbs, but lymphedema it is not restricted to the extremities. 
Lymphedemas are divided into two different types based on their origin; primary 
lymphedema is caused by mutations related to lymphatic vascular development 
genes and secondary lymphedema occurs after surgical operations or other 
types of damage that compromise lymphatic vessel function. 
Mutations in about twenty different genes have been associated with different 
types of primary lymphedemas. Mutations of VEGFR3 are the most common 
reason for lymphedema (Brouillard et al., 2014). In a subset of these mutations, 
lymphedema is only one symptom caused by the abnormal gene function 
(Connell et al., 2013). Missense kinase-inactivating mutations in Vegfr3 have 
been described in so-called Chy mice (Karkkainen et al., 2000). These mice 
were used as a model for primary lymphedema characterization and treatment 
because their mutation and phenotype resembles those in a large subset of 
human primary lymphedema patients (Brouillard et al., 2014; Irrthum et al., 
2000; Karkkainen et al., 2001). Mutations of VEGFR3 are the most common 
reason for Milroy’s disease and its subtypes, which are congenital type of 
lymphedemas that involve lower limb swelling (Irrthum et al., 2000; Karkkainen 
et al., 2000). Whereas the Chy mice lack lymphatic vessels in the skin, in 
Milroy’s disease patients the initial lymphatic vessels are present but they are 
non-functional (Karkkainen et al., 2001; Mellor et al., 2010). Rare mutations of 
Vegfc can also cause a Milroy-like disease, which is impossible to distinguish 
clinically from the Vegfr3 mutations (Gordon et al., 2013). Another gene closely 
to related to the VEGF-C/VEGFR-3 axis is the Ccbe1. It has been shown that 
Ccbe1 is important factor for VEGF-C processing (Jeltsch et al., 2014). 
Mutations of this gene have been shown to cause the Hennekam-syndrome. 
Patients with the Hennekam-syndrome have early-onset lymphedema, 
lymphangiectasia and mental retardation (Alders et al., 2009). Foxc2 mutations 
cause late-onset primary lymphedema with some other characteristic symptoms 
like distichiasis (Brice et al., 2002). Mice that lack the Foxc2 gene have irregular 
lymphatic vessel patterning, abnormal pericyte interaction and defects in valve 
formation in the collecting lymphatic vessels (Petrova et al., 2004). VEGFR-3 
has been shown to genetically interact with FoxC2 in LECs (Petrova et al., 
2004). Recently it has been shown that Foxc2 is important for vessel 
stabilization by mechanotransductive signals induced by lymph flow (Sabine et 
al., 2015). Besides these genes, several others are involved in normal 
lymphatic vessel development and mutations of these genes cause primary 
lymphedema in humans (Aspelund et al., 2016; Brouillard et al., 2014; Connell 
et al., 2013). 
 
An acquired lymphedema not related to genetic mutations is called secondary 
lymphedema, which is due to physical disruption, radiation damage, infection, 
or prolonged inflammation followed by fibrosis. A common form of secondary 
lymphedema can be found in a breast cancer patient who has undergone a 
surgical procedure in which the axillary LNs have been removed. Up to 30% of 
these patients develop lymphedema of the arm (Petrek and Heelan, 1998). In 
these individuals, lymphatic vessels commonly dilate and become dysfunctional 
(Ikomi et al., 2006). The scale of the breast cancer operation correlates with the 
severity of the condition. In addition, in geographically restricted secondary 
lymphedema cases in the tropics, e.g. in Africa and South-America, parasitic 
?? ??
nematodas, transmitted by mosqitoes, can target lymphatic vessels and lymph 
nodes, preventing the normal flow of lymph and causing tissue swelling and 
fibrosis (Shenoy, 2008). Currently, only a very limited number of treatment 
options are available for lymphedema patients via interfering the VEGF-
C/VEGFR-3 pathway.  
Inflammation associated lymphangiogenesis (IAL) 
 
Lymphangiogenesis is known to take place during inflammatory processes (Kim 
et al., 2014). This context-dependent and dynamic process can eventually have 
a major role in tissue healing (Kim et al., 2014). IAL occurs in response to a 
variety of inflammatory stimuli. For example, upon Gram-negative bacterial 
infection, several cell types produce high levels of lymphangiogenic growth 
factors because of bacterial lipopolysaccharide and cytokine exposure. Upon 
cytokine-induced recruitment, macrophages and granulocytes enhance further 
VEGF-C expression in the inflamed tissue (Baluk et al., 2005) 
Lymphangiogenesis in inflammatory settings facilitates the resolution of tissue 
edema, and it promotes macrophage and DC mobilization to draining LNs 
(Huggenberger et al., 2011; Kataru et al., 2009). However, IAL modulation has 
a great impact on the inflammation clearance. In the skin, blocking of the VEGF-
C/VEGFR-3 pathway prolongs tissue swelling in the oxazolone-induced 
hypersensitivity model, and, on the other hand, VEGF-C overexpression 
accelerates inflammation clearance (Huggenberger et al., 2011; Huggenberger 
et al., 2010). In inflammatory bowel disease (IBD) models, exogenous VEGF-C 
attenuates progression of the pathogenesis (D'Alessio et al., 2014). In contrast, 
reduction of macrophages that produce lymphangiogenic growth factors boosts 
the inflammation (Becker et al., 2016). It has further been shown that during 
mycoplasma-induced airway inflammation, lymphatic vessels remodel their 
junctions (Baluk et al., 2005). Fourteen days after infection with Mycoplasma 
pulmonis, the sprouting lymphatic vessels had zipper-type junctions instead of 
buttons, but the change was reversed by antibody treatment against VEGFR-3 
(Baluk et al., 2005). Thus, the lymphatic vessels show great plasticity during 
inflammation.  
 
IAL seems to be involved also in tissue rejection after organ transplantation. An 
extensive lymphangiogenic response is associated with transplant rejection 
(Kerjaschki et al., 2004). Blocking of pathological lymphangiogenesis has been 
shown to be an effective treatment for preventing rejection of, for example, 
heart (Nykanen et al., 2010) and cornea transplants (Hos et al., 2015). The 
clinical potential of lymphatic vessels needs to be recognized, especially in the 
transplantation field. 
Lymphatic vessels in obesity and lipid homeostasis 
 
Obesity is the result of an imbalance between calorie uptake and energy 
consumption. The first evidence showing an interaction between the genes that 
control lymphatic vessel development and those that contribute to the onset of 
adiposity and obesity came from studies of  Chy mice (Karkkainen et al., 2001) 
and Prox1+/− mice (Harvey et al., 2005), respectively. The latter phenotype was 
recently reversed by expression of a Prox1 transgene in lymphatic endothelium, 
which prevented the late-onset obesity (Escobedo et al., 2016). Prox1+/- mice 
have dysfunctional lymphatic vessels and continuous leakage of chyle, which 
has been shown to be adipogenic in vitro, into the interstitial space (Harvey et 
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al., 2005) The obese phenotype has not been observed in other mice with 
lymphatic vessel dysfunction such as the Chy, K14-VEGFR3-Ig, or Vegfc 
heterozygous mice (Aspelund et al., 2016). Prox1 is known to be expressed in 
many other metabolically active tissues, including the heart and skeletal muscle 
(Risebro et al., 2009), which could explain the obesity phenotype. Lymph has 
been shown to promote adipogenesis in the Prox1+/- mice (Escobedo et al., 
2016; Harvey et al., 2005) and Chy mice have more adipocytes in 
subcutaneous tissue (Karkkainen et al., 2001). These findings suggest that 
lymphatic vessel dysfunction and lymph leakage promotes adipogenesis, but 
clear molecular evidence is still lacking.  
 
It was recently reported that lymphatic vessels function in reverse cholesterol 
transport (RCT) (Lim et al., 2013; Martel et al., 2013). In these studies, 
lymphatic vessel dysfunction correlated with the impaired RCT in genetic and 
surgical models, demonstrating the essential role that lymphatic vessels have in 
cholesterol metabolism. This finding could link dysfunctional lymphatic vessels 
to the progression of atherosclerosis (Randolph and Miller, 2014). Previous 
studies have indicated that hypercholesterolemic mice have lymphatic vessel 
dysfunction and degeneration (Lim et al., 2009). A recent study has also 
proposed that soluble VEGFR-2 extracellular domain has a crucial role in 
controlling VEGF-C levels in atheroma-related lymphangiogenesis in mice 
(Taher et al., 2016). In humans, expression of lymphatic vessel markers 
increases in the areas where the plaques are located, indicating counter play 
between lesion formation and subsequent lymphatic vessel growth (Grzegorek 
et al., 2014). Thus, clearly, the lymphatic vessels are involved in lipid 
metabolism and related disorders, but more thorough investigations are 
required to uncover the molecular pathways that would provide clinical benefit.  
Other diseases related to VEGF-C/VEGFR-3 pathway 
 
Lymphatic vessels and therefore also the VEGF-C/VEGFR-3 pathway are 
becoming the focus of new interest in other diseases as well. Below, I briefly 
describe some of the new hot topics in the field. 
 
The recently discovered meningeal lymphatic vessels (Aspelund et al., 2015; 
Louveau et al., 2015) have triggered intense discussion of their function, 
especially in pathological settings. In neurodegenerative Alzheimer’s disease 
and neuroinflammatory multiple sclerosis, the immune system has been shown 
to play a pivotal role, and the lymphatic vessels have been speculated to be 
involved in both (Louveau et al., 2016). However experimental evidence from 
the pre-clinical models does not yet exist.  
 
Lymphatic vessel growth in the eye, mainly in the cornea, has been investigated 
in great detail during the past years (Bock et al., 2013). Corneal (blood and 
lymphatic) vessel growth occurs in several pathological conditions such as in 
corneal crafts and in aging-related diseases (Bock et al., 2013). New evidence 
shows that corneal transplantations are more successful after blocking the 
VEGF-C/VEGFR-3 pathway (Hos et al., 2015). After the discovery of 
Schlemm’s canal as a VEGFC/VEGFR-3-dependent drainage pathway from the 
anterior chamber of the eye (Aspelund et al., 2014; Park et al., 2014), intense 
research has tried to validate its role in intra-ocular pressure regulation.   
 
?? ??
The C-type Lectin Receptor 2 (CLEC-2) was recently found to be responsible 
for the maturation of collecting lymphatic vessels in mouse embryos by inducing 
blood clotting when blood tries to enter lymphatic vessels at the lymphovenous 
border (Sweet et al., 2015). In pathological settings, this may be relevant in the 
case of a surgical trauma of the thoracic duct, in heart failure, and in 
lymphomas (Doerr et al., 2005). Under pathologically elevated venous 
pressures, lymphovenous clot formation may become more crucial for 
maintaining blood/lymph separation. If lymphovenous hemostasis is inhibited by 
antiplatelet/anticoagulant treatment or pathological hemostatic defects, 
dysfunction of the lymphatic vessels may be exacerbated, contributing to 
lymphedema (Welsh et al., 2016).  
 
Thus, specific drug and treatment candidates can be used to treat lymphatic 
vessels in certain pathological conditions such as cancer and lymphedema. In 
cardiovascular diseases, obesity and inflammation, lymphatic vessels have also 
been found to be affected and in the near future this knowledge will hopefully 
translate into new clinical applications. Recent findings on lymphatic vessels in 
the central nervous system have raised hopes for new potential applications in 
diseases where the lymphatic vascular system has not yet been targeted. 
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AIMS OF THE STUDIES 
 
The specific aims of my thesis studies have been listed below. 
 
I. To clarify how VEGFR-3 contributes to angiogenesis  
 
II. To determine the role of the VEGF-C/VEGFR-3 pathway in 
atherosclerosis using mice in which this pathway is interfered 
 
III. To elucidate whether VEGF-C is necessary for lymphatic vessel 
maintenance in adult mice, in addition to its crucial role during lymphatic 
vessel development  
 
IV. To investigate erythropoiesis in Vegfc gene deleted mice based on their 
pale appearance relative to their littermates 
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MATERIALS AND METHODS 
 
The materials and methods are described in detail in the original publications. 
Tables of the most relevant materials and methods are provided below, 
followed by detailed protocols of the methods used most. 
Materials 
 
Table I. Mouse lines 
 
Csf1op/op  Mice with a spontaneous 
osteopetrosis mutation  
(Wiktor-
Jedrzejczak et 
al., 1982) 
I 
Foxc2+/- Foxc2 gene deletion (Iida et al., 
1997) 
I 
K14-Vegfr3-Ig  Over-expression of the human 
VEGFR3-Ig protein under the K14 
promoter in skin 
(Makinen et al., 
2001a) 
II 
LDLR-/-/ApoB100/100 Mice expressing an APO-B100 
transgene and are deficient in low- 
density lipoprotein receptor 
(Veniant et al., 
1998) 
II 
PdgfbiCreERT2 Inducible Cre recombinase under the 
control of Pdgfb gene promoter 
(Claxton et al., 
2008) 
I 
Rosa26-CreERT2 Inducible Cre recombinase under the 
control of Rosa26 gene promoter 
(Ventura et al., 
2007) 
III,IV 
Rosa26-R Reporter mice expressing β-
calactosidase (LacZ) gene after Cre-
recombination 
(Soriano, 1999) I 
Rosa26LSL-tdTomato Expression of TdTomato gene after 
Cre-recombination 
(Madisen et al., 
2010) 
IV 
Vav-Cre Constitutive Cre recombinase under 
the control of Vav gene promoter 
(de Boer et al., 
2003) 
IV 
Vegfc+/LacZ Vegfc heterozygous mice in which β-
calactosidase (LacZ) gene has been 
inserted into the Vegfc locus 
(Karkkainen et 
al., 2004) 
I,III,IV 
Vegfc flox/flox Mice with conditionally targeted 
Vegfc alleles 
(Aspelund et al., 
2014) 
III,IV 
Vegfd+/- Heterozygous Vegfd gene deleted 
mice 
(Baldwin et al., 
2005) 
I,III 
Vegfr2+/LacZ β-calactosidase (LacZ) gene has 
been use to replace one allele of the 
Vegfr2 gene 
(Shalaby et al., 
1995) 
I,III,IV 
Vegfr3+/LacZ   β-calactosidase (LacZ) gene has 
been used to replace one allele of 
the Vegfr3 gene   
(Dumont et al., 
1998) 
I,III,IV 
Vegfr3+/KD Mice have a missensepoint mutation 
in the tyrosine kinase domain of 
Vegfr3 (A3157T) 
(Karkkainen et 
al., 2001) 
I,II 
Vegfr3 flox/flox Vegfr3 conditionally targeted mice (Haiko et al., 
2008) 
I,III,IV 
NMRI,CD1,C57bl,FVB/n Wild type mice  Taconic, Envigo I,III,IV 
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Table II. Antibodies 
 
Activated Caspase 3, 
mouse 
Rabbit polyclonal R&D Systems, AF835 IV 
BrdU Mouse monoclonal, Alexa 
Fluor 594 conjugated 
Invitrogen, B35132, 
clone MoBU-1 
I 
c-Kit, mouse Goat, biotinylated R&D Systems, AF1356 IV 
CD3, mouse Rabbit monoclonal Abcam, ab16669 II 
CD45, mouse Rat polyclonal BD Pharmigen, 550566 IV 
Collagen IV, mouse Rabbit polyclonal Cosmo Bio (Lb, 1403) I 
Dll4, mouse Goat polyclonal R&D systems AF1389 I 
E-Cadherin, mouse Purified mouse BD Pharmigen, 610181 IV 
Endomucin, mouse Rat monoclonal Santa Cruz, sc-65495 I 
F4/80, mouse Rat monoclonal AbD Serotec, MCA497R I, IV 
FITC Rabbit polyclonal Invitrogen, 71-1900 I 
FOXC2, mouse  (Furumoto et al., 1999) I 
GFP Rabbit polyclonal Torrey Pined Biolabs 
TP401 
I 
hF4-3C5, human Mouse humanized 
monoclonal 
ImClone systems 
(Persaud et al., 2004) 
I 
LYVE1, mouse Rabbit polyclonal Reliatech, 103-PA50AG II 
LYVE1, mouse Rabbit polyclonal (Karkkainen et al., 2004) III,IV 
mMQ (Macrophages) Rabbit polyclonal ACSC, AIA31240 II 
PECAM-1, mouse Rat monoclonal BD Biosciences 553370, 
clone MEC 13.3 
I, II, III,IV 
PECAM-1, mouse Hamster monoclonal Millipore, MAB1398Z IV 
Prox-1, human Goat polyclonal R&D systems, AF2727 III 
SMA, mouse Mouse Cy3-conjugated Sigma, C6189 III 
TIE2, mouse Rat monoclonal eBioscience, CD202b, 
Clone:TEK4 
I 
VEGFC, human Rabbit polyclonal, #6 (Baluk et al., 2005) I 
VEGFR2, mouse Goat polyclonal R&D systems, AF644 IV 
VEGFR2, mouse Rat monoclonal (Prewett et al., 1999); 
CD101 
I 
VEGFR3, mouse Goat polyclonal R&D Systems, AF 743 I, III, IV 
VEGFR3, mouse Rat monoclonal (Pytowski et al., 2005) 
Clone mF4-31C1 
I 
Ter-119, mouse Rat polyclonal BD Pharmigen, 550565 IV 
Von Willebrand Factor Rabbit polyclonal DAKO, A0082 IV 
Conjugated secondary 
antibodies 
Chicken, Donkey, Goat – 
488,594,647 labeled  
Invitrogen I.II.III,IV 
 
Table III. Cell lines, recombinant viruses, recombinant proteins and inhibitors 
 
CELL LINES 
B16-F10-Luc-G5 Luciferase expressing mouse 
melanoma cells 
Caliper Life I 
HDBEC Human dermal blood vascular 
endothelial cells 
Promo Cell I 
LLC Mouse Lewis lung carcinoma cells ATCC I 
mESC Mouse embryonic stem cells 
derived from blastocysts 
(Holmborn et al., 
2004) 
I 
VIRAL VECTORS 
AdVEGF165 Human VEGF165 - Adenovirus (Enholm et al., 
2001) 
I 
AdVEGFB167 Human VEGFB167 - Adenovirus (Lahteenvuo et al., I 
?? ??
2009) 
pMX-Dll4 ECTM-
EGFP 
pMX retrovirus that encodes mouse 
Dll4-ECTM-EGFP 
(Zheng et al., 
2011a) 
I 
AAV-sVEGFR3 Mouse sVEGFR3 - AAV (Aspelund et al., 
2014) 
IV 
RECOMBINANT 
PROTEINS 
Dll4-Fc Mouse Dll4 fused to Fc domain of 
human IgG  
(Zheng et al., 
2011b) 
I 
Jagged 1 A Notch activating synthetic 
peptide 
(Weijzen et al., 
2002) 
I 
sc-Jagged1 Scrambled sequence for Jagged1. 
peptide 
(Weijzen et al., 
2002) 
I 
VEGF165 Recombinant human VEGF R&D systems I 
VEGFCΔNΔC Fully processed form of human 
VEGFC 
(Karpanen et al., 
2006a) 
I 
SMALL MOLECULE 
INHIBITOR 
Sunitinib Multi targeted receptor tyrosine 
kinase inhibitor 
Pfizer III 
Methods 
 
Table IV. Summary of methods 
 
Adenoviral transduction of mice I 
Cell culture I, IV 
Cell transfections and transductions I 
Characterization of a new transgenic mouse strain III 
Clinical chemistry II 
FACS analysis IV 
Functional analysis of lymphatic vessels II, III 
Histological analysis of mouse aortas II 
Immunoluoresence/immunohistochemistry I - IV 
Immunoprecipitation and immunoblotting I  
In Vivo studies I - IV 
Microscopy I - IV 
Mouse embryo stimulation with growth factors/gene deletions I, IV 
Lipid analysis III 
PI3K activity assay I 
Polymerase chain reaction I - IV 
Production and purification of Dll4-Fc I 
Real-time quantitative PCR I, III, IV 
Statistical analysis I - IV 
Tumor experiments I 
X-gal staining of the tissues I, III, IV 
 
Cell culture 
 
Primary human blood vascular endothelial cell (hBEC) experiments.  
hBECs (PromoCell) were maintained in endothelial cell growth medium (ECGM, 
PromoCell) with supplements provided by the manufacturer. For the stimulation 
experiments, hBECs were starved in serum-free ECGM for 4 h and stimulated 
for 1 or 2 h with different growth factors in starvation medium. For the silencing 
? ??
experiments, hBECs were transfected with human VEGFR3 or non-targeted 
siRNA (Thermo Scientific Dharmacon siGENOME ON-TARGETplus 
SMARTpool reagents), using Oligofectamine (Invitrogen). Gene expression was 
examined 48 h post-transfection by qRT-PCR of cell lysates in RLT buffer 
(Qiagen). Alternatively, cells were lysed in PLCLB lysis buffer (150mM NaCl, 
5% glycerol, 1% Triton X-100, 1.5 M MgCl2, 50 mM HEPES, pH 7.5, 1mM 
Na3VO4, phenylmethylsulphonyl fluoride, leupeptin and aprotinin) for 
immunoprecipitation. 
 
Methocult CFU assay 
Freshly isolated cells from E14.5 fetal livers, yolk sac (YS) and E10.5 embryos 
were plated in duplicates in 1 ml of MethoCult GF M3434 medium or SF M3436 
medium according to the manufacturer’s instructions (Stemcell Techonologies). 
Colonies were studied and counted at days 3, 10, and 14. 
 
Functional analysis of the lymphatic vessels 
 
Peripheral lymphatic vessel function was determined by injecting Evans Blue 
(30 μl, 30 mg/ml in 0.7% sodium chloride (NaCl)) into footpads of anesthetized 
mice. After 30 min, the mice were euthanized and transport of the dye to the 
thoracic duct was evaluated. For lipid absorption test in the gut, mice were pre-
treated with WR1339 (Tyloxapol;Sigma) at 500 mg/kg intraperitoneal (i.p) for 
lipase inhibition one hour prior to oil Gavage. 
 
Histological analysis of the mouse aortas 
 
Mice were euthanized with carbon dioxide (CO2) or decapitation or perfused 
with phosphate-buffered saline (PBS) after over dose of anesthetics through the 
left ventricle. Aortas were dissected from the aortic arch to bifurcation and fixed 
in 4% PFA-PBS overnight. Aortas were opened longitudinally and attached to a 
black surface. For hematoxylin-eosin, modified Movat’s pentachrome and 
immunohistochemical stainings, tissue samples were collected in 4% PFA-PBS 
for overnight fixation, processed to paraffin blocks and cut into 4 or 7 μm 
sections. For Oil-red-O staining, tissue samples were snap-frozen in liquid 
nitrogen and cut into 10 μm frozen sections. Cross-sectional lesion areas were 
quantified from aortic roots stained with hematoxylin-eosin. Percentage of the 
lesion area in the intima was calculated from tissue sections at the aortic sinus 
level, defined by the presence of three valve cusps. Vascular outward 
remodeling was determined by measuring the area within the internal elastic 
lamina. 
 
Immunofluorescence/Immunohistochemistry 
 
Tissue sections ranging between 10 and 100 μm in thickness were fixed 
overnight with 4% PFA or with cold acetone immediately before the staining, 
washed with PBS and blocked with TNB (PerkinElmer). Sections were washed 
with TNT buffer and the primary antibodies were detected with the appropriate 
Alexa 488, 594 or 647 secondary antibody conjugates (Molecular 
Probes/Invitrogen). Whole mount tissues were fixed overnight in 4 % 
paraformaldehyde (PFA), followed by washeing in PBS and staining with 
antibodies in donkey immune mix. For analysis of the retinal microvasculature, 
tissues were stained with biotinylated Griffonia simplicifolia lectin (Vector 
?? ??
Laboratories), followed by immunostaining. All fluorescently labeled samples 
were mounted with Vectashield containing 4,6-diamidino-2-phenylindole (DAPI, 
Vector Laboratories).  
 
In vivo studies  
 
Cre-recombinase activation 
For induction of CreERT2 mediated recombination in embryos, the mother was 
injected at the indicated days with two consecutive intragastric doses of 4-OH 
tamoxifen (4-OHT) (Sigma) (25 mg/ml dissolved in 100 μl of ethanol/olive oil). In 
the neonatal mice, the Cre-mediated recombination was induced between P1 
and P5 by daily intragastric administration of 4-OHT (2 µl at 25 mg/ml dissolved 
in ethanol). Recombination in adult mice (7–8 weeks old) was done by 
intragastric tamoxifen (Sigma, dissolved in 100 µl of corn oil at 2 mg/ml) 
administration during five consecutive days. In some experiments, Cre was 
induced by subcutaneous implantation of sustained tamoxifen-release pellets. 
 
Tumor experiments 
B16-F10-Luc2-G5 mouse melanoma or mouse LLC cells were maintained in 
DMEM, supplemented with 2 mM L-glutamine, penicillin (100 U/ml), 
streptomycin (100 μg/ml), and 10% fetal calf serum (Promo Cell). For B16-F10-
Luc2-G5 cells, zeocin was added at a final concentration of 0.3 mg/ml as a 
selection marker. The B16 and LLC syngeneic tumor grafts were established by 
injecting 2-4*106 cells into the subcutaneous space of the abdominal flank. 
 
High Fat Diet (HFD) studies 
For the HFD experiments, the mice were treated with tamoxifen at the age of 7-
8 weeks. The diet (60% fat, D12492, Research Diets Inc.) was started 
approximately 4 weeks later and continued for an additional 8 weeks. The 
glucose tolerance test (1g/kg; GTT) and the insulin tolerance test (0.75 U/kg; 
ITT) were performed after 6 hours of fasting. Feces were collected for lipid 
analysis. Mouse body composition was analyzed by dual-energy x-ray 
absorptiometric (DEXA) densitometry (Lunar PIXImus 2, GE Heathcare) after 8 
weeks of HFD. For lipid absorption test, mice were pre-treated with WR1339 
(Tyloxapol;Sigma) 500 mg/kg i.p. for lipase inhibition one hour prior to oil 
Gavage. 
 
Treatment with the receptor tyrosine kinase (RTK)-inhibitor Sunitinib was done 
by daily intra-gastric administration at a concentration of 60 mg/kg for 14 days. 
Sunitinib was diluted to 1,8% NaCl, 0,1 % Tween20, 0,5 carboxy-methyl 
cellulose solution. Control-treated mice were administered the same solution 
without Sunitinib. 
 
Stress anemia model 
Phenylhydrazine hydrochloride (PHZ; 60 mg/kg, i.p) or 5- 
fluorouracil (5-FU; 150 mg/kg, intraperitoneally) was injected into adult  
mice at the age of 13 and 16 weeks, respectively. Peripheral blood (PB) was 
collected from the saphenous vein into heparinized capillaries (Hirschmann 
laborgerate) every 3 days after PHZ or 5-FU treatment. Analysis was then 
performed using Exigo automated blood analyzer (Boule Medical AB). 
 
 
? ??
Microscopy 
 
Immunofluorescence images were taken with a compound fluorescent 
microscope (Zeiss Axioplan 2, Carl Zeiss; 5x objective with numerical aperture 
(NA) 0.15; 10x 0.30) or a confocal microscope (Zeiss LSM 510Meta, objectives 
10x with NA 0.45, oil objectives 10x with NA 1.3 and 63x with NA 1.4 or with a 
Zeiss LSM780 (10x with NA:0.45  20X with NA:0.80). Three-dimensional 
projections were digitally reconstructed from confocal z stacks. Bright-field 
sections were viewed with a Leica DM LB microscope (Leica Microsystems), 
and images were captured with an Olympus DP50 color camera (Olympus Soft 
Imaging Solutions GMBH). 
 
Mouse embryo stimulation  
 
E10.5-E11.5 NMRI wild-type embryos were excised from amnionic sacs and 
placed in Dulbecco's modified Eagle's medium (DMEM) containing 0.2% bovine 
serum albumin (BSA) on ice. The embryos were injected through the outflow 
tract with 0.5 ml of DMEM containing recombinant proteins. Embryos were 
placed in DMEM containing the same concentration of growth factors, 
incubated at 37oC for 20 min and then lysed in lysis buffer. Insoluble materials 
were removed by centrifugation at 14 000g for 15 min. 
 
Real-time quantitative PCR 
 
Total RNA from tissues or cultured cells was isolated using the RNeasy Mini Kit 
(Qiagen) or NucleoSpin RNA II Kit (Macherey-Nagel). Homogenization was 
carried out using rotor-stator homogenization, followed by on-column DNase 
digestion (RNase-Free DNase Set, 79254). Quality control of samples was 
carried out using a Nanodrop ND-1000 spectrophotometer. RNA was reverse-
transcribed using the DyNAmo cDNA Synthesis Kit or according to the 
manufacturer's instructions. Three qRT-PCR reactions were carried out from 
every in vitro transcription reaction using TaqMan Gene Expression Assays 
(Applied Biosystems) and the DyNAmo Probe qPCR Kit (F-450S, Finnzymes) or 
the iQ Supermix Kit. qRT-PCR was carried out using a BIO-RAD C1000 
Thermal cycler according to a standardized protocol. 
 
Statistical analysis 
 
Quantitative data were compared between groups by two-tailed unpaired t-test 
or one-way ANOVA followed by post hoc tests for multiple comparisons. Values 
are expressed as mean +/- SEM or +/- SD. P-value < 0.05 was considered 
significant. 
 
X-gal staining of the tissues 
 
Tissues were dissected and immersed into cold washing buffer (1M MgCl2, 1% 
deoxycholate, 2% Nonidet P-40, 0.1 M Phosphate buffer pH 7.3) and then fixed 
in fixing solution (25% glutaraldehyde, 100mM EGTA pH 7.3, 1M MgCl2, 0,1M 
phosphate buffer pH 7.3) for 4 h at RT, washed 3x15 minutes with washing 
buffer, stained with X-Gal solution overnight at 37oC for β-galactosidase activity. 
Alternatively, fixing was done at +4oC. and the staining at RT. Tissues were 
then washed for 8-24 h in washing buffer and fixed with 4% PFA overnight at 
?? ??
+4oC. Next day, samples were washed with PBS and processed for paraffin 
embedding. 
 
A detailed description of the methods can be found in the original publications ?
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RESULTS AND DISCUSSION 
Study I: VEGFR-3 is required for blood vessel formation 
via Notch signaling 
 
New blood vessels rise mainly from pre-existing ones via sprouting during 
angiogenesis (Chung and Ferrara, 2011). The irreplaceable key players in this 
process are VEGF (Carmeliet et al., 1996; Ferrara et al., 1996) and its primary 
receptor VEGFR-2 (Gille et al., 2001). Hierarchical growth of the developing 
vascular bed is crucial for proper vascular function. Hierarchy is based on 
specification of the tip and stalk cells of the sprouts (Jakobsson et al., 2009). 
This is controlled by VEGF induced delta-like 4 (Dll4) expression in the tip cells 
and Notch1 activation in the stalk cells (Jakobsson et al., 2009). The role of 
VEGFR-3 in blood vessel development is evident from embryonic studies, 
where Vegfr3 deletion led embryonic death as early as E9.5 (Dumont et al., 
1998). Whereas in intrauterine development VEGFR-3 expression is later 
restricted lymphatic vessels (Kaipainen et al., 1995), has been shown that 
inhibition of VEGFR-3 can inhibit also pathological angiogenesis to some extent 
(Tammela et al., 2008). On the other hand VEGFR-3 has been linked to 
sprouting angiogenesis via Notch signaling (Tammela et al., 2008) and it has 
been proposed to have a suppressing role that prevents overactivation of 
VEGFR-2 in the blood vessel (Matsumura et al., 2003). 
 
In this study, we show that genetic deletion of Vegfr3 from BECs leads to blood 
vascular hyperplasia with increased vessel sprouting, branching, and cell 
proliferation in the neonatal mouse retina angiogenesis model (Figure 1, I). This 
was also confirmed by careful examination of the developing vascular beds in 
the Chy-mice (Karkkainen et al., 2001), which have reduced signaling capacity 
in the VEGFR-3 pathway (Figure 2, I). These results conflict with previous 
findings that show that blocking of the VEGFR-3 pathway with antibodies 
inhibits angiogenesis (Tammela et al., 2008).  
 
Phosphorylation of the VEGFR-2 was increased when VEGFR-3 was deleted 
from the endothelial cells, explaining the increased vascular phenotype of the 
Vegfr3-deleted mice (Figure 3, I). Our model indicates that when the VEGFR-3-
mediated signaling is inactive, the potent VEGFR-2 signaling pathway is more 
active, resulting in increased endothelial cell growth. Loss of VEGFR-3 signaling 
from endothelial cells decreases expression of the Notch target genes Hey1, 
Hey2, and Nrarp, and a rescue experiment with Jagged1, a small Notch agonist 
peptide, reversed the effect of Vegfr3 gene deletion, confirming the interplay 
between VEGFR-3 and Notch1 (Figure 4, I). It seems that VEGFR-3 
suppresses VEGFR-2 signaling, and this balances the Notch cascade. 
However, if the VEGFR-3 pathway is blocked by genetic deletion, Notch-based 
suppression is not functional in the stalk cell compartment. VEGF-C stimulation 
of VEGFR-3 in BECs led to Notch activation and decreased sensitivity to VEGF 
signaling (Benedito et al., 2009; Tammela et al., 2008). However, this 
phenotype was only obtained by genetic deletion of Vegfr3, whereas blocking 
antibodies against VEGFR-3 did not produce similar effects (Tammela et al., 
2008). This indicates that blocking of the receptor or its genetic deletion lead to 
different outcomes in the developing vascular plexuses. Blocking of VEGFR-3 
with antibodies or kinase inhibitors can only target the active part of VEGFR-3 
?? ??
signaling, whereas the passive part of the signaling can be eliminated only via 
genetic deletion of the Vegfr3. 
 
Thus, although VEGF-C is the main factor responsible for lymphatic vessel 
growth (Karkkainen et al., 2004), we show in this study that reduced levels of 
VEGF-C, by using the Vegfc+/LacZ mouse, cause a delay in normal blood vessel 
development in the neonatal retina, including decreased branching and Notch 
target gene expression (Figure 5, I). This phenotype differs from the endothelial 
cell Vegfr3 deletion phenotype, which instead causes increasing sprouting of 
developing vascular bed. VEGF-C expression was found to be restricted to 
macrophages in the retina, being especially prominent at the fusion sites of the 
developing vessels. The fully processed form of VEGF-C can bind to VEGFR-2 
(Joukov et al., 1996; Joukov et al., 1997). Manipulating the Vegfc levels did not 
entirely recapitulate the receptor deficiency, but instead led to growth 
retardation in the vascular plexuses. In both cases, the Notch activation pattern 
and normal tip/stalk cell contribution were altered.  
 
Later studies have deepened our understanding about the interplay between 
VEGFR2 and VEGFR3 in angiogenesis. In 2012, Notch-dependent VEGFR3 
upregulation was reported to allow angiogenesis without VEGF-VEGFR2 
signaling (Benedito et al., 2012); however, a contradictory study revealed that 
VEGFR2 is required independently of VEGFR3 signaling for endothelial Dll4 
upregulation and angiogenic sprouting (Zarkada et al., 2015). This later study 
speculates about the discrepant findings and concludes that major differences 
exist in some technical aspects (Zarkada et al., 2015). The differences between 
these studies could be explained by the incomplete VEGFR2 deletion and the 
specificity of the tools (e.g. the tyrosine kinase inhibitor) used to inactivate 
VEGFR3 in the previous studies.  
 
Study I provides more thorough understanding of how VEGFR-3 regulates the 
conserved VEGF/VEGFR-2 pathway in angiogenesis, but further analysis is 
required to elucidate the exact molecular interactions contributing to the 
angiogenesis between VEGFRs and the Notch pathway. VEGFR3 signaling in 
BECs could be regulated by specific intra-cellular interactions of tyrosine 
residues that activate downstream signaling differentially depending of the 
context.  This could lead to development of new clinical innovations by 
manipulating the VEGFR-3 in pathological angiogenesis.  
 
Study II: Lymphatic vessel deficiency in mice promotes 
atherosclerosis  
 
Cardiovascular diseases (CVDs) and cancer are the leading causes of mortality 
in Western countries. The progression of atherogenesis has been characterized 
well during the past decades. High low-density lipoprotein (LDL) levels in the 
blood predisposes to lipid accumulation to the intima of arteries, which later is 
followed by macrophage infiltration and active proliferation of the smooth 
muscle cells (Lusis, 2000). Active angiogenesis has been shown to occur at 
sites of atheroma development (Moulton, 2006), but so far the role of lymphatic 
vessels in this process has been poorly described. In this study, our aim was to 
investigate how atheromas develop upon lymphatic vessel insufficient mouse 
strains in a hypercholesterolemic mouse strain fed HFD. 
? ??
 
First, we were able to show that in Chy mice (Karkkainen et al., 2001) 
cholesterol levels are significantly higher than in their WT littermates prior to 
HFD and K14-VEGFR-3-Ig (Makinen et al., 2001a) mice showed a similar 
increased cholesterol level trend in comparison with their littermates after the 
HFD (Figure 1, II). When the K14-VEGFR3-Ig mice was then crossed with a 
hypercholestrolemic LDLR-/-/ApoB100/100 background, they showed a similar 
pattern triglyceride levels prior and after the HFD (Figure 2, II). The lipoprotein 
profile in the K14-VEGFR3-Ig; LDLR-/-/ApoB100/100 mice were compared with that 
in the LDLR-/-/ApoB100/100 mice. An increased LDL fraction was observed in K14-
VEGFR3-Ig; LDLR-/-/ApoB100/100 mice (Figure 3, II) and the subsequent en face 
analysis of the large arteries indicated larger atheromas in the aorta in these 
mice. The most striking differences were observed when the mice were 
challenged with HFD in young or middle age and especially in the early stages 
of the disease (Figure 4, II). This indicates that lymphatic vessels and elevated 
lipoprotein levels have a strong impact on the onset of the atheroma formation.  
 
The other atheroma mouse model ApoE-/- has been shown to have impaired 
lymphatic drainage and abnormal lymphatic vessels in the skin (Lim et al., 
2009). This shows that there is a connection between elevated cholesterol 
levels and lymphatic dysfunction. This was the first indication that high 
lipoprotein levels and lymphatic vessels interact. Later, it was discovered that 
the lymphatic vessels have an important role in reverse cholesterol transport 
(RCT) and this transport function was meditated by SR-B1 (Lim et al., 2013). 
The lymphatic vessel-deficient Chy mice have also been shown to have 
impaired RCT, and the difference seems to be meditated by macrophages 
(Martel et al., 2013). Another study revealed that immune cell trafficking, one 
important function of lymphatic vessels that is crucial for atheroma formation, is 
compromised in K14-VEGFR3-Ig mice (Thomas et al., 2012). 
 
It is thus obvious that dysfunctional lymphatic vessels affect elevated lipoprotein 
levels in the blood circulation and that RCT is impaired when lymphatic vessels 
are lacking or poorly functional. Our results show that the lymphatic vessels are 
present in the areas where the plaques are develop and that soluble VEGFR3 
prevents lymphatic neovascularization (Figure 6, II). The more rapidly 
advancing atheromas in the K14-VEGFR3; LDLR-/-/ApoB100/100 mice might be 
generated because the dysfunctional lymphatic vessels cannot clear lipids from 
the developing plaques.  
 
So far, human studies have shown increased levels of VEGF-C, VEGF-D, and 
LYVE-1 in postmortem atheroma samples compared with healthy controls 
(Grzegorek et al., 2014). This indicates that cytokine secretion activates the 
lymphatic system and this later causes increased lymphangiogenesis via 
directional sprouting and vessel growth towards the inflamed atheroma plaque 
combined with lymphocyte/macrophage trafficking in atherosclerosis 
(Grzegorek et al., 2014). Preliminary studies from mice propose that 
extracellular vesicles could be used as biomarkers for inflammatory progression 
and as an indicator for lymphatic vessel dysfunction (Milasan et al., 2016). 
 
Open questions remain regarding the interplay between lymphatic vessels and 
CVDs. For example, how do lymphatic endothelial cells contribute to plaque 
development? Is increased lymphangiogenesis in the atheroma lesions 
?? ??
beneficial for disease prevention, and how does RCT act in atheroma plaques 
compared with healthy tissues? These questions should be answered by using 
more sophisticated models in order to determine whether lymphatic vessels can 
actively clear the adverse lipid particles from the atheroma and to what extent? 
In murine models, however, it is not possible to mimic all of the aspects of 
atherosclerosis, as we know that the disease progression and also the tissue 
itself differ from those in humans.  
 
Overall our study revealed that lymphatic vessels are an active player in the 
progression of atherosclerosis and they can be seen as a potential target for 
clinically relevant treatments of atherosclerosis.   
 
Study III: Intestinal lymphatic vessels need constant 
VEGF-C/VEGFR-3 pathway signaling for maintenance 
and function 
 
Already more than a decade ago it was shown that VEGF-C is indispensable for 
lymphatic vessel development (Karkkainen et al., 2004). VEGF-C driven 
pathological lymphangiogenesis has been under profound investigation 
especially in the field of lymphedema and cancer metastasis research, where 
VEGF-C or its inhibition may provide possibilities for disease therapy (Alitalo, 
2011). However attempts to understand the role of VEGF-C expression in 
quiescent tissues have not been made to the same degree, mainly because 
tools for this have been lacking. One of the main tasks of lymphatic vessels is 
the lipid absorption from the gut. This task is carried out by special blind-ended 
capillaries, called lacteals, which differs from the other lymphatic capillaries, for 
example in their junctions, which are zipper-like (Bernier-Latmani et al., 2015; 
Choe et al., 2015). Lacteals are located in the villus, the epithelial cell covered 
extension in the intestinal wall, where they are covered by blood capillary 
network (Kamba et al., 2006). The entering of the chylomicron particles in the 
lacteals has been shown to use both paracellular and transport meditated 
delivery strategies (Dixon, 2010). In this decade there have been reports about 
unexpected function of lymphatic vessels in the homeostasis. We generated the 
conditional Cre-Lox Vegfc mouse to address the question about the role of 
VEGF-C in adult tissues (Aspelund et al., 2014). In this study, we wanted to 
clarify the role of Vegfc in adult mice, especially in the gut, where lymphatic 
vessels are under constant stress because of active nutrient absorption (Dixon, 
2010).  
 
We first showed that the Vegfc targeted conditional alleles are effectively 
deleted pre- and postnatally in the intestine used as the model organ. Our 
findings showed that developing lymphatic vessels are dependent on VEGF-C 
in all stages of their development. The surprising finding however was that the 
intestinal lymphatic vessels, both lacteals and the vessel plexus in the intestinal 
wall, goes through atrophy when Vegfc expression is eliminated in the adult and 
this phenotype was aggravated in the Vegfd deficient background (Figure 1, III 
and Figure 3). The atrophy was restricted to the initial lymphatic vessels of the 
gut and it did not occur for example in the skin even after prolonged deletion 
periods.  
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Figure 3. VEGF-C is required for intestinal lymphatic vessel maintenance in adult mice. 
A-H) Lymphatic vessels staining with LYVE1 after global Vegfc deletion in the intestinal wall of 
adult mice. Detailed information about genotypes and deletion durations are provided in Study 
III. I) Quantification of LYVE1 areas in A–H. Duration of the Vegfc deletion is indicated in 
months (mo), and Vegfd indicates the VEGF-D genotype. Scale bar 400 μm. Data are 
represented as mean +/- SEM. *P > 0.05 vs. WT. 
 
Dynamic control of the lymphatic vessel maintenance in the gut was later 
confirmed by using a Dll4 conditional mouse model, where lacteals start to 
regress in adult mice after lymphatic vessel specific Dll4 deletion (Bernier-
Latmani et al., 2015). The simultaneous finding from our group indicates that 
Vegfr3 deletion in adult tissues reduces lymphatic vessel caliper in the skin and 
trachea (Zarkada et al., 2015) suggests that lymphatic vessel signaling 
mechanism differ between different organs. This finding is important regarding 
the possible clinical applications, as it emphasizes the consideration of how 
different vascular plexuses behave under inhibition of the VEGF-C/VEGFR3 
signaling pathway. 
 
 A second important finding was that in adult animals, Vegfc expression is 
restricted to the smooth muscle cell compartment (Figure 2, III). Previous Vegfc 
expression studies have been carried out only in embryos (Karkkainen et al., 
2004; Le Bras et al., 2006), and this was the first time that we were able to 
locate the exact source of VEGF-C expression in the gut. The intestinal 
lymphatic vessel atrophy was a slow process and by itself did not affect the 
overall well-being of the mouse, despite the fact that the intestinal lymphatic 
vessels have a crucial role in fat absorption from the gut. We challenged these 
mice with HFD and observed that the weight gain of the Vegfc deficient mice 
was slower and their obesity related metabolic parameters were improved when 
compared to their littermates, which have normal lymphatic vessels. An obvious 
consequence of the lymphatic phenotype was that the cholesterol and free fatty 
acid levels in the stools were increased because of their impaired absorption in 
the gut (Figure 3, III). Lacteal shortening and intestinal wall lymphatic vessel 
diminution were shown to be crucial for proper lipid absorption, however we 
could not exclude additional effects of the VEGF-C in the intestine. To our 
surprise, lipid accumulation was not observed in the intestinal stroma, 
suggesting a signaling mechanism that regulates lipid uptake to enterocytes, 
adjusting it to further transport level inside the intestinal villus.  
 
?? ??
These findings as such highlight the differences between lymphatic vessels in 
different parts of the body and on the other hand raise the question of the 
pathophysiology of the intestinal lymphatic vessels. It has been shown in mouse 
models that inflammatory bowel disease (IBD) affects the gut lymphatic vessels 
and by blocking expansion of these vessels via interrupting the VEGF-C 
signaling the symptoms become more severe (D'Alessio et al., 2014). The role 
of lymphatic vessel expansion during IBD was described already decades ago 
(Van Kruiningen and Colombel, 2008), but comprehensive understanding has 
been lacking about the molecular dynamics underlying this event. 
 
Additional studies are required to reveal how vascular growth factors and 
intestinal lymphatic vessels are involved in gut homeostasis and in the 
pathological process beyond nutrient absorption. 
 
Study IV: VEGF-C functions in embryonic 
erythropoiesis  
 
Twenty years ago, it was shown that especially VEGF (Ferrara et al., 1996) and 
VEGFR-2 (Shalaby et al., 1995) are essential in the early steps of 
hematopoiesis development. In mammals there are three waves of 
hematopoiesis, namely the primitive, transient and definitive stages (Tober et 
al., 2007) and a host of factors regulate these processes (Palis, 2014). However 
open questions still remain in the regulation mechanisms that influence the 
primitive blood cell migration, proliferation and differentiation in several 
hematopoietic sites in the developing embryo. In mouse embryos, constitutive 
Vegfc deletion causes embryonic lethal phenotype around E16 (Karkkainen et 
al., 2004). Heterozygous Vegfc mice survive, but not in Mendelian ratio or in all 
backgrounds, for example in the C57Bl/6 background for unknown reason 
(Karkkainen et al., 2004). Our aim was to clarify if Vegfc has other necessary 
functions during embryogenesis beyond the lymphatic vessel development. By 
using a Cre-Lox conditional Vegfc mouse (Aspelund et al., 2014) we tackled 
this question by inducing Vegfc deletion as early as on embryonic day (E) 7.5 in 
the C57bl/6 background.   
 
Besides an evident edema phenotype, we observed a tremendous decrease in 
liver size by day E13.5, which was further found to occur because of decreased 
erythropoiesis involving increased apoptosis of erythrocytes and their 
supporting macrophages (Figure 1, IV and Figure 4). When we analyze the 
peripheral blood of these embryos, we detected increased amounts of 
nucleated red blood cells in the circulation and overall signs of immature 
erythropoiesis (Figure 2, IV). This was later confirmed with the aid of flow 
cytometry and qPCR analysis (Figure 3 IV). These findings were similar to 
observations regarding the impairment of erythropoiesis shown previously in 
CCBE1 (Zou et al., 2013) and ADAMTS3 (Janssen et al., 2016) deleted mice. 
Both of these molecules are actively involved in the proteolytic processing of 
VEGF-C (Aspelund et al., 2016).  
 
By using the conditional Vegfc deletion, we next investigated the sensitive time 
period when Vegfc is required for normal erythropoiesis. To our surprise we did 
not observe deficient erythropoiesis when Vegfc deletion was induced at E10.5 
or later. Further, our investigation showed that VEGF-C has a crucial role in 
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fetal liver colonization of the erythroid-myeloid progenitors (EMPs) and later, in 
the expansion of the macrophage population in the liver (Figure 4, IV). It has 
been previously reported that α4β1 and α5β1 integrins are important for 
erythropoiesis (Eshghi et al., 2007; Ulyanova et al., 2011). Our data indicated 
that α4 integrin levels were reduced in erythromyeloid progenitors (EMPs) after 
VEGF-C deletion.  
 
 
?
Figure 4. Decreased fetal liver size after global deletion of Vegfc at E7.5.  
A-B) Representative images of embryos and their livers at E13.5 and E15.5 after global Vegfc 
deletion (VciΔR26) at E7.5.  
 
We summarized our findings in a model in which VEGF-C regulation of 
erythropoiesis happens in a yolk sac, in embryonic blood circulation, and later in 
the fetal liver. Vegfc acts via influencing ?4 integrin levels and fetal liver 
colonization of EMPs, and, later on, erythrocyte maturation (Figure 5, IV). Taken 
together, our data indicate that Vegfc is a major regulator in fetal erythropoiesis, 
but not in adult erythropoiesis in homeostatic conditions. Further studies are 
required to determine whether the VEGF-C/VEGFR-3 signaling pathway 
regulates the bone marrow stem cell niche in the adult mouse. These studies 
will require specific experiments that challenge the bone marrow, as it is the 
main regulator of blood cell production in adult animals.  
 
These findings revealed an unexpected role of the VEGF-C in the regulation of 
embryonic erythropoiesis. It has not earlier been shown that this molecule, 
which is responsible for lymphatic vessel expansion during development 
(Karkkainen et al., 2004) has such an important role in blood cell formation. The 
signaling cascade behind this event was surprising, as it seems to indicate a 
rather minor role of the well-known VEGF-C-VEGFR2/VEGFR3 pathway in this 
process. A scheduled deletion scheme enabled this investigation, and it might 
?? ??
be that more precise investigation of the VEGFR2/VEGFR3 pathway will 
pinpoint some similarities regarding the erythropoiesis phenotype.  
 
In adult animals, erythropoiesis is restricted mainly to the bone marrow. Further 
investigation is required to analyze the possible role of VEGF-C in 
hematopoietic stem cell regulation under hematopoietic stress. 
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CONCLUDING REMARKS  
 
Studies described in this thesis have deepened our knowledge regarding the 
VEGF-C/VEGFR-3 pathway in embryo development and pathological 
conditions. Previously it was well established that VEGF-C is necessary for 
lymphatic vessel development (Karkkainen et al., 2004) and that VEGFR-3 is 
necessary for normal embryonic blood vessel development even prior its 
function in lymphatic vessel growth (Dumont et al., 1998). Findings reported in 
this thesis have brought new insights to the essential functions of VEGF-C and 
VEGFR-3.  
 
In the first study of this dissertation, we show how VEGFR-3 is a critical 
modulator of normal angiogenesis during developmental angiogenesis and in 
the last study we show that VEGF-C has a previously unidentified role in the 
regulation of the embryonic erythropoiesis. Both of these studies revealed new 
and previously unknown roles of these molecules during development. These 
findings expand our view in terms of the basic research and the new information 
might turn out to be later useful for clinical therapeutics development. Targeting 
VEGFR-3 in pathological angiogenesis may be advantageous compared with 
targeting the traditional VEGF/VEGFR-2 pathway, which strongly affects healthy 
and normal blood vessels by e.g. increasing leakage.  The VEGF-C/VEGFR-3 
axis may have important functions in the pathogenesis of obesity and 
cardiovascular disease. The second study of this dissertation highlights the role 
of lymphatic vessels in the formation of atheromas. Based on these results, the 
deficiency on the lymphatic vessel function enhances atherosclerosis. This 
brings up the question for the possible medical opportunities to increase 
lymphatic vessel function to prevent the plaque formation or even to reduce 
already existing plaques. We could also show that constant VEGF-C/VEGFR-3 
signaling is needed for proper lipid absorption from the intestine. When 
interruption occurs in the VEGF-C/VEGFR-3 pathway, lipid absorption is 
decreased by the atrophy that develops in the intestinal lymphatic vessels. 
Further studies are required for better understanding of how lymphatic vessels 
and the VEGF-C/VEGFR-3 pathway contribute also to intestinal inflammation.  
 
These results have increased our understanding of the functions of 
lymphangiogenic growth factors. Especially Studies II, III, and IV have revealed 
previously unknown interactions and phenomena requiring further investigations 
to gain a comprehensive overview of the role of the VEGF-C/VEGFR-3 
signaling pathway in these biological incidents. 
 
My humble wish is that these findings will benefit the research community and 
eventually the well-being of human patients with various diseases. 
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